MBD3 inhibits formation of liver cancer stem cells

Ruizhi Li; Qihua He; Shuo Han; Mingzhi Zhang; Jinwen Liu; Ming Su; Shiruo Wei; Xuan Wang; Li Shen

doi:10.18632/oncotarget.13496

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MBD3 inhibits formation of liver cancer stem cells

Ruizhi Li, Qihua He, Shuo Han, Mingzhi Zhang, Jinwen Liu, Ming Su, Shiruo Wei, Xuan Wang and Li Shen _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:6067-6078. https://doi.org/10.18632/oncotarget.13496

Metrics: PDF 2080 views | HTML 3784 views | ?

Abstract

Ruizhi Li1, Qihua He1, Shuo Han1, Mingzhi Zhang1, Jinwen Liu2, Ming Su1, Shiruo Wei1, Xuan Wang3, Li Shen1

1Stem Cell Research Center, Department of Cell Biology, School of Basic Medical Sciences, Peking University, Haidian District, Beijing, 100191, China

2Beijing DongFang YaMei Gene Science and Technology Research Institute, Beijing, People’s Republic of China

3State Key Laboratory of Organ Failure Research, Co-Innovation Center for Organ Failure Research, Guangdong Provincial Southern Medical University, Guangzhou, Guangdong Province, People’s Republic of China

Correspondence to:

Li Shen, email: [email protected]

Keywords: induced liver cancer stem cells, MBD3/NuRD, c-JUN, C3A, transcriptional regulation

Received: July 28, 2016 Accepted: October 19, 2016 Published: November 22, 2016

ABSTRACT

Liver cancer cells can be reprogrammed into induced cancer stem cells (iCSCs) by exogenous expression of the reprogramming transcription factors Oct4, Sox2, Klf4 and c-Myc (OSKM). The nucleosome remodeling and deacetylase (NuRD) complex is essential for reprogramming somatic cells. In this study, we investigated the function of NuRD in the induction of liver CSCs. We showed that suppression of methyl-CpG binding domain protein 3 (MBD3), a core subunit of the NuRD repressor complex, together with OSKM transduction, induces conversion of liver cancer cells into stem-like cells. Expression of the transcription factor c-JUN is increased in MBD3-depleted iCSCs, and c-JUN activates endogenous pluripotent genes and regulates iCSC-related genes. These results indicate that MBD3/NuRD inhibits the induction of iCSCs, while c-JUN facilitates the generation of CSC-like properties. The iCSC reprogramming approach devised here provides a novel platform for dissection of the disordered signaling in liver CSCs. In addition, our results indicate that c-JUN may serve as a potential target for liver cancer therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13496

Publication Alerts

Research Papers:

MBD3 inhibits formation of liver cancer stem cells

Abstract